• HIV-1 program is the prime focus
• Clear clinical development program designed to demonstrate to regulators and pharma how the drug
may be used to improve health outcomes in combination with ART
• SARS-CoV-2 program is developing drugs with potential to reduce virus levels and immune dysfunction
seen in moderate to severe COVID. Aim is to progress these as quickly as possible through relevant
models and into formal safety studies.
• Hepatitis B (HBV) remains a promising and important early-stage program and good progress has been
made to select a robust lead candidate
• Biotron clearly has a portfolio of antivirals which uniquely combine antiviral inhibition with
immunomodulatory activity.
• All activities are undertaken with aim of generating data for partners.
- Forums
- ASX - By Stock
- BIT
- Ann: Chairman's Address and Presentation to AGM
Ann: Chairman's Address and Presentation to AGM, page-5
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.85M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.2¢ | $20.69K | 940.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 537628 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 141604 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 537628 | 0.021 |
8 | 454100 | 0.020 |
10 | 1899381 | 0.019 |
7 | 234054 | 0.018 |
4 | 408000 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 141604 | 1 |
0.024 | 439576 | 4 |
0.025 | 600000 | 3 |
0.026 | 53847 | 1 |
0.027 | 162000 | 2 |
Last trade - 15.51pm 28/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |